134 related articles for article (PubMed ID: 38305197)
1. Potential anticancer effect of free and nanoformulated Deferasirox for breast cancer treatment:
Abdel-Wahab ND; Kabil MF; El-Sherbiny IM; Salama MF; El-Sayed G; El-Sherbini ES
Drug Dev Ind Pharm; 2024 Mar; 50(3):223-235. PubMed ID: 38305197
[TBL] [Abstract][Full Text] [Related]
2. Switching indication of PEGylated lipid nanocapsules-loaded with rolapitant and deferasirox against breast cancer: Enhanced in-vitro and in-vivo cytotoxicity.
Kabil MF; Mahmoud MY; Bakr AF; Zaafar D; El-Sherbiny IM
Life Sci; 2022 Sep; 305():120731. PubMed ID: 35753435
[TBL] [Abstract][Full Text] [Related]
3. Biochemical effects of deferasirox and deferasirox-loaded nanomicellesin iron-intoxicated rats.
Rahdar A; Hajinezhad MR; Sargazi S; Bilal M; Barani M; Karimi P; Kyzas GZ
Life Sci; 2021 Apr; 270():119146. PubMed ID: 33545199
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
Dou H; Qin Y; Chen G; Zhao Y
Acta Haematol; 2019; 141(1):32-42. PubMed ID: 30504715
[TBL] [Abstract][Full Text] [Related]
5. Destructive effect of iron overload in brain tissue of albino rats: Ameliorative role of silver immobilized organo-modified casein nanocomposite as co-treating agent with Deferasirox.
Adel RM; Lotfy RA; Darwish AS; Amer AS
J Trace Elem Med Biol; 2021 Sep; 67():126794. PubMed ID: 34052583
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
Wu D; Wen X; Liu W; Hu H; Ye B; Zhou Y
Drug Des Devel Ther; 2018; 12():1081-1091. PubMed ID: 29760547
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
Chen CH; Shu KH; Yang Y
Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
[TBL] [Abstract][Full Text] [Related]
9. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
Zhou N; Cui Y; Zhu R; Kuang Y; Ma W; Hou J; Zhu Y; Chen S; Xu X; Tan K; Cao P; Duan X; Fan Y
Gynecol Oncol; 2022 Jul; 166(1):126-137. PubMed ID: 35688655
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
Lin CH; Chen X; Wu CC; Wu KH; Song TS; Weng TF; Hsieh YW; Peng CT
Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
[TBL] [Abstract][Full Text] [Related]
11. Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.
Nolte F; Nückel H; Schmidt B; Geer T; Rubanov O; Hebart H; Jarisch A; Albrecht S; Johr C; Schumann C; Hofmann WK
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1531-1538. PubMed ID: 29761371
[TBL] [Abstract][Full Text] [Related]
12. Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.
Cheng WY; Said Q; Hao Y; Xiao Y; Vekeman F; Bobbili P; Duh MS; Nandal S; Blinder M
Curr Med Res Opin; 2018 Nov; 34(11):1959-1966. PubMed ID: 29701080
[TBL] [Abstract][Full Text] [Related]
13. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox.
Amano S; Kaino S; Shinoda S; Harima H; Matsumoto T; Fujisawa K; Takami T; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2020 Jul; 20(1):681. PubMed ID: 32698792
[TBL] [Abstract][Full Text] [Related]
14. Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Elli EM; Di Veroli A; Bartoletti D; Iurlo A; Carmosino I; Benevolo G; Abruzzese E; Bonifacio M; Bergamaschi M; Polverelli N; Caramella M; Cilloni D; Tiribelli M; Pugliese N; Caocci G; Crisà E; Porrini R; Markovic U; Renso R; Auteri G; Cattaneo D; Trawinska MM; Scaffidi L; Biale L; Bucelli C; Breccia M; Gambacorti-Passerini C; Palumbo GA; Latagliata R; Palandri F
Br J Haematol; 2022 Apr; 197(2):190-200. PubMed ID: 35137397
[TBL] [Abstract][Full Text] [Related]
15. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
Gao HY; Li Q; Chen JJ; Chen GF; Li CG
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?
Di Veroli A; Campagna A; De Muro M; Maurillo L; Trawinska MM; LeonettiCrescenzi S; Petriccione L; Romano A; D'Addosio A; Cenfra A; Montanaro M; Felici S; Andriani A; Carmosino I; Niscola P; Montefusco E; Breccia M; Latagliata R
Leuk Res; 2019 Jan; 76():65-69. PubMed ID: 30578958
[TBL] [Abstract][Full Text] [Related]
17. Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload.
Watanabe J; Sato K; Horiuchi T; Kato S; Hikota R; Maekawa T; Yamamura T; Kobayashi A; Osawa Y; Kobayashi S; Kimura F
Int J Hematol; 2014 Sep; 100(3):254-9. PubMed ID: 24986748
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
Merchant R; Ahmed J; Krishnan P; Jankharia B
Indian Pediatr; 2012 Apr; 49(4):281-5. PubMed ID: 21992861
[TBL] [Abstract][Full Text] [Related]
19. Dose of deferasirox correlates with its effects, which differ between low-risk myelodysplastic syndrome and aplastic anaemia.
Zhang R; Han B
J Clin Pharm Ther; 2022 Oct; 47(10):1619-1626. PubMed ID: 35748618
[TBL] [Abstract][Full Text] [Related]
20. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]